|
UPDATE: Least Costly Alternative (LCA) in Local Coverage Decisions
The Centers for Medicare and Medicaid Services (CMS) determined they will no longer enforce least costly alternative (LCA) policies as of 4/19/2010.
CMS Contractor Pinnacle Business Solutions, Inc. reports on their website:
Based on instructions from CMS, Local Coverage Determinations (LCDs) in which ‘Least Costly Alternative’ provisions exist are to be changed. The following LCDs will be retired (AR/LA Part B), not finalized (AR-Part A), or removed from comment period (LA/MS Part A) with an effective date of 4/19/2010.
1. AC-07-004 LHRH Analogs, Agonists, and Antagonists for Treatment of Malignant Neoplasm of the Prostate (L26245)
2. ARA-07-004 LHRH Analogs, Agonists, and Antagonists for Treatment of Malignant Neoplasm of the Prostate (DL30746)
3. PBSI-A-10-045 LHRH Analogs, Agonist, and Antagonists for Treatment of Malignant Neoplasm of the Prostate (DL31046)
This change comes after a December 2009 court ruling that sided with a Medicare beneficiary regarding her treatment option. The case of Hays v. Sebelius involved Medicare denying a patient a prescribed treatment for her serious lung disease. Medicare, in complete contrast to the physician’s advice, decided to pay for the Least Costly Alternative (LCA). The court ruled in favor of the plaintiff and the decision by Medicare was overruled.
Therefore, effective, 4/19/2010 all Medicare carriers will reimburse LH-RH Analogs at the CMS published quarterly provider update associated with their individual J-Codes.
|